Exacerbation requiring ED or hospital visit Weighted mean duration of studies: 31 weeks · people with asthma
It is very uncertain whether sublingual immunotherapy changes exacerbation requiring ED or hospital visit Weighted mean duration… compared with control (very low certainty).
1 finding from 1 review
Quality of life · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events Weighted mean duration of studies: 49 weeks · people with asthma
Sublingual immunotherapy showed no clear difference in serious adverse events Weighted mean duration of studies: 56 weeks compared with control (moderate certainty).
1 finding from 1 review
Exacerbation requiring OCS Weighted mean duration of studies: 25 weeks · people with asthma
It is very uncertain whether sublingual immunotherapy changes exacerbation requiring OCS Weighted mean duration of studies: 58 weeks compared with control (very low certainty).
1 finding from 1 review
All adverse events Weighted mean duration of studies: 60 weeks** · people with asthma
Sublingual immunotherapy leads to higher all adverse events Weighted mean duration of studies: 62 weeks** compared with control (high certainty).
1 finding from 1 review
Bronchial provocation · people with asthma
1 finding from 1 review
ICS use · people with asthma
1 finding from 1 review
Health‐related quality of life · participants with chronic cough
Speech and language therapy may leads to higher health‐related quality of life compared with healthy lifestyle advice (low certainty).
1 finding from 1 review
Serious adverse events · participants with chronic cough
1 finding from 1 review
Objective cough counts (over 24‐hour period) · participants with chronic cough
1 finding from 1 review
Symptoms · participants with chronic cough
1 finding from 1 review
Clinical improvement (as defined by trialists) · participants with chronic cough
It is very uncertain whether speech and language therapy changes clinical improvement (as defined by trialists) compared with healthy lifestyle advice (very low certainty).
1 finding from 1 review
Cough · participants with chronic cough
Speech and language therapy showed no clear difference in subjective measures of cough (e.g. VAS/numerical cough scale score) compared with healthy lifestyle advice (low certainty).
1 finding from 1 review
Cough reflex sensitivity (as measured by cough challenge: capsaicin concentration required to provoke 5 coughs) · participants with chronic cough
1 finding from 1 review
Adverse events · participants with chronic cough
1 finding from 1 review
Outcomes (weighted · stable COPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Moderate‐to‐severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower moderate‐to‐severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Severe exacerbations (rate) · stable COPD
Triple therapy may leads to lower severe exacerbations (rate) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline (lower scores indicate better HRQoL) · stable COPD
Triple therapy leads to higher respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline… compared with LABA/LAMA combination (high certainty).
1 finding from 1 review
Pneumonia (labelled as an SAE) · stable COPD
Triple therapy probably leads to higher pneumonia (labelled as an SAE) compared with LABA/LAMA combination (moderate certainty).
1 finding from 1 review